Examples of using Pitolisant in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Pitolisant should not be used during pregnancy unless the potential benefit outweighs the potential risk for foetus.
The active substance, pitolisant, attaches to receptors on cells in the brain that are involved in stimulating alertness.
The combination of pitolisant with substrates of CYP3A4 and having a narrow therapeutic margin should be avoided see section 4.5.
Pitolisant exhibits high serum protein binding(>
included 165 patients 67 treated with pitolisant, 33 with placebo and 65 with modafinil.
Pitolisant is not a significant inhibitor of OAT1,
Patients with abnormal levels of sleepiness who take pitolisant should be advised that their level of wakefulness may not return to normal.
Pitolisant shows greater than 50% inhibition towards OCT1(organic cation transporters 1) at 1.33 µM, the extrapolated IC50 of pitolisant is 0.795 µM see section 4.5.
Based on in vitro data, pitolisant and its main metabolites may induce CYP3A4
In narcoleptic patients with or without cataplexy, pitolisant improves the level
Several conjugated metabolites were identified, the major ones(inactive) being a glycine conjugate of the acid metabolite of O-dealkylated desaturated pitolisant and a glucuronide of a ketone metabolite of monohydroxy desaturated pitolisant. .
including those taking pitolisant should be frequently reassessed for their degree of sleepiness
The effect size of pitolisant compared with placebo based on a model for WRC based on BOCF with centre as a fixed effect was 0.581,
Juvenile toxicity studies in rats revealed that the administration of pitolisant at high doses induced a dose related mortality
the effect size of pitolisant compared with placebo was summarized by the ratio rate rR(Pt/Pb),
The effectiveness of pitolisant up to 36 mg once a day, for the treatment of narcolepsy with
The results with pitolisant were significantly superior to those in the placebo group(mean difference:
The following adverse reactions have been reported with pitolisant during clinical studies enrolling more than 1094 patients in narcolepsy
The exposure to pitolisant in healthy volunteers was assessed in studies involving more than 200 subjects that received doses of pitolisant in single administration up to 216 mg and for a duration up to 28 days.
Pitolisant has a plasma half-life of 10-12 hours.